Alzheimer’s Disease

Alzheimer's disease is the most common cause of dementia (60-80%), a general term for memory loss and other cognitive abilities serious enough to interfere with daily life. The patient's condition gets worse over time, affecting memory, thinking and behavior, ultimately leading to irreversible very severe cognitive decline [AD is the sixth leading cause of death in the U.S.].
At a brain level, Alzheimer’s disease is characterized by an accumulation of the protein beta-amyloid outside neurons and twisted strands of the protein tau inside neurons are hallmarks. They are accompanied by the death of neurons and brain tissue damage. Alzheimer's Disease triggers additional alterations, such as brain tissue inflammation and atrophy.
In the past three years, three anti–amyloid beta (Aβ) immunotherapies have demonstrated their benefit in phase 3 clinical trials. Benefits were increasing for each drug, which have started to receive FDA approval. It is likely that these therapies will all be more and more approved in the US, in Europe and possibly in other world regions in the near future, transforming the Alzheimer's Disease management landscape.

The current breakthrough in the field will soon redefine disease management, raising new scientific challenges for radiologists & neurologists.
The most recent outcomes from clinical trials indicate, for the first time, that anti-amyloid treatment could slow down cognitive decline. This breakthrough changes the paradigm of Alzheimer’s treatment and offers hope both for patients and families. This transformation however presents scientific and clinical challenges, requiring the implementation of a complex treatment plan, especially when it comes to brain imaging monitoring.

At TheraPanacea we leverage state of the art technology to unlock AI powered solutions to enhance the workflow of R&D teams & clinicians!